Zhitong Finance App News, Fosun Pharmaceutical (600196.SH) announced that on August 16, 2026, Fuhong Hanlin, a holding subsidiary of the company, signed a “Cooperation Framework Agreement” with Sandoz AG, which will enable registration, commercialization, development, and production of up to 10 monoclonal antibodies (mAb) and/or antibody-conjugated drug (ADC) biosimilar products or ingredients (i.e. “cooperative products”) with Sandoz AG in overseas relevant regions, and has already collaborated on the first batch of 3 cooperative products (i.e. HLX05-N, HLX16) Specific commercial terms were agreed with Bellyumab (a drug similar to antibiotics), and a potential cooperative product (i.e. HLXTE-Haase1001) was granted the right of choice to Sandoz AG.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.